HighTower Advisors
CHRS icon

HighTower Advisors’s Coherus Oncology CHRS Stock Holding History

HighTower Advisors’s Portfolio CHRS Stock Details CHRS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q4 		– Sell
-11,775
Closed -$189K – 3321
2021
Q3 		$189K Buy
11,775
+325
+3% +$4.76K ﹤0.01% 2732
2021
Q2 		$158K Hold
11,450
– – ﹤0.01% 2715
2021
Q1 		$167K Hold
11,450
– – ﹤0.01% 2656
2020
Q4 		$199K Hold
11,450
– – ﹤0.01% 2206
2020
Q3 		$210K Hold
11,450
– – ﹤0.01% 2058
2020
Q2 		$205K Sell
11,450
-80
-0.7% -$1.35K ﹤0.01% 1982
2020
Q1 		$185K Buy
11,530
+6
+0.1% +$111 ﹤0.01% 1815
2019
Q4 		$207K Sell
11,524
-1,544
-12% -$28.5K ﹤0.01% 1952
2019
Q3 		$264K Buy
13,068
+884
+7% +$17.7K ﹤0.01% 1879
2019
Q2 		$268K Buy
12,184
+734
+6% +$12.7K ﹤0.01% 1862
2019
Q1 		$156K Hold
11,450
– – ﹤0.01% 2011
2018
Q4 		$104K Buy
11,450
+1,100
+11% +$12.7K ﹤0.01% 1951
2018
Q3 		$171K Hold
10,350
– – ﹤0.01% 1983
2018
Q2 		$145K Hold
10,350
– – ﹤0.01% 1962
2018
Q1 		$114K Buy
+10,350
New +$113K ﹤0.01% 1958

Other funds holding CHRS

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Temasek Holdings
Temasek Holdings Singapore $30.5B AUM 13.98% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
AllianceBernstein
AllianceBernstein Nashville, Tennessee $309B AUM 23.92% 1-Year Est. Return
PA
Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
KKRC
Kohlberg Kravis Roberts & Co New York $5.35B AUM 63.01% 1-Year Est. Return
ACB
Aristotle Capital Boston Boston, Massachusetts $1.61B AUM 19.82% 1-Year Est. Return
Ameriprise
Ameriprise Minneapolis, Minnesota $432B AUM 30.22% 1-Year Est. Return

HighTower Advisors's CHRS Position: Q4 2021 in Review

HighTower Advisors sold out of Coherus Oncology (CHRS) in Q4 2021, closing a stake of 11,775 shares — an estimated $189K sold.

HighTower Advisors first reported a position in CHRS in Q1 2018 and held it in 15 quarters. The position peaked at $268K in Q2 2019. 201 funds tracked by Wall St. Rank hold CHRS as of Q4 2021.

  • HighTower Advisors reported no remaining Coherus Oncology position as of Q4 2021 after selling out during the quarter.
  • HighTower Advisors sold 11,775 Coherus Oncology shares in Q4 2021, an estimated $189K.
  • HighTower Advisors first reported a position in Coherus Oncology in Q1 2018 and held it in 15 quarters.
  • HighTower Advisors's Coherus Oncology position peaked at $268K in Q2 2019.
  • 201 funds tracked by Wall St. Rank held Coherus Oncology as of Q4 2021.

Based on HighTower Advisors's 13F filing for Q4 2021, filed 10 Feb 2022.